Table 3.
Demographics and clinical characteristics of the donors included in the SSc cohort 3.
| Patient group (n) | HC (21) | eaSSc (15) | ncSSc (27) | lcSSc (23) | dcSSc (19) |
|---|---|---|---|---|---|
| Age (yr.) | 52 (35–82) | 62 (25–81) | 59 (29–80) | 60 (41–80) | 52 (27–80) |
| Female (n, %) | 19 (90%) | 15 (100%) | 27 (100%) | 22 (96%) | 15 (79%) |
| ANA (n pos, %) | – | 15 (100%) | 26 (96%) | 22 (96%) | 16 (84%) |
| ACA (n pos, %) | – | 12 (80%) | 20 (74%) | 12 (52%) | 0 (0%) |
| Scl70 (n pos, %) | – | 2 (13%) | 1 (4%) | 9 (39%) | 11 (58%) |
| mRSS | – | 0 | 0 | 4 (0–8) | 12 (2–29) |
| ILD | – | 0 | 2 (7%) | 7 (30%) | 14 (74%) |
| Disease Duration (yr.) | – | N.A. | 10* (0–29) | 16** (1–38) | 10 (1–25) |
Values reported indicate the number (n) of patients and the median for each parameter [Interquartile Range (IQR)], if not otherwise indicated. ACA, anticentromere antibodies; ANA, antinuclear antibodies; dcSSc, diffuse cutaneous SSc; eaSSc, early SSc; HC, healthy controls; ILD, Interstitial Lung disease; lcSSc, limited cutaneous SSc; mRSS, modified Rodman Skin score; N.A., not assessed; ncSSc, non-cutaneous SSc; pos, positivity; Scl70, anti-topoisomerase antibodies; Yr., years.
*
2 patients unknown.
**
3 patients unknown.